08.11.2017 | Methotrexat | Klinische Studien
Janus-Kinase-Inhibitor Baricitinib bei rheumatoider Arthritis
Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy (RA-BEAM)
Erschienen in: Die Innere Medizin | Ausgabe 12/2017
Einloggen, um Zugang zu erhalten